Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients

J. A. Erkens; O. H. Klungel; R. M. Herings; R. P. Stolk; J. A. Spoelstra; D. E. Grobbee; H. G. Leufkens

doi:10.1053/euhj.2002.3173

Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients

J. A. Erkens, O. H. Klungel, R. M. Herings, R. P. Stolk, J. A. Spoelstra, D. E. Grobbee, H. G. Leufkens

Epidemiology and Data Science

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

AIMS: The aim of the present study was to investigate whether use of specific antibiotic drugs decreases the risk of coronary heart disease in diabetes mellitus type 2 patients. METHODS AND RESULTS: Data were obtained from the PHARMO Record Linkage System comprising pharmacy records and hospitalizations for all 450,000 residents of eight Dutch cities. In a nested case-control study among diabetes mellitus type 2 patients, 244 cases with a first hospitalization for coronary heart disease and 686 controls without coronary heart disease matched on age, sex, calendar time, and registration date in PHARMO RLS were selected. Use of antibiotic drugs among cases and controls was determined over 3 years prior to the event. Use of fluorquinolones for more than 14 days compared to no use of fluorquinolones was associated with a lower risk of coronary heart diseases (OR(adj)=0.30 (95%CI: 0.12-0.75)). No association between tetracycline, macrolide and lincosamide treatment, or other antibiotic drugs (penicillins, cephalosporines, sulphonamides and trimethoprim), and the risk of coronary heart disease was found. CONCLUSION: Our results suggest that treatment with fluorquinolones in doses commonly prescribed in routine clinical practice is associated with a reduction in the risk of coronary heart diseases among diabetes mellitus type 2 patients.

Original language	English
Pages (from-to)	1575-1579
Number of pages	5
Journal	European Heart Journal
Volume	23
Issue number	20
DOIs	https://doi.org/10.1053/euhj.2002.3173
Publication status	Published - 2002

Access to Document

10.1053/euhj.2002.3173

https://www.ncbi.nlm.nih.gov/pubmed/12323156

Cite this

@article{e27413812d354defb88b9ca3194e8718,

title = "Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients",

abstract = "AIMS: The aim of the present study was to investigate whether use of specific antibiotic drugs decreases the risk of coronary heart disease in diabetes mellitus type 2 patients. METHODS AND RESULTS: Data were obtained from the PHARMO Record Linkage System comprising pharmacy records and hospitalizations for all 450,000 residents of eight Dutch cities. In a nested case-control study among diabetes mellitus type 2 patients, 244 cases with a first hospitalization for coronary heart disease and 686 controls without coronary heart disease matched on age, sex, calendar time, and registration date in PHARMO RLS were selected. Use of antibiotic drugs among cases and controls was determined over 3 years prior to the event. Use of fluorquinolones for more than 14 days compared to no use of fluorquinolones was associated with a lower risk of coronary heart diseases (OR(adj)=0.30 (95%CI: 0.12-0.75)). No association between tetracycline, macrolide and lincosamide treatment, or other antibiotic drugs (penicillins, cephalosporines, sulphonamides and trimethoprim), and the risk of coronary heart disease was found. CONCLUSION: Our results suggest that treatment with fluorquinolones in doses commonly prescribed in routine clinical practice is associated with a reduction in the risk of coronary heart diseases among diabetes mellitus type 2 patients.",

keywords = "Aged Case-Control Studies Control Groups Coronary Disease/*prevention & control Diabetes Mellitus, Type 2/*drug therapy Diabetic Angiopathies/*prevention & control Female Fluoroquinolones/*therapeutic use Humans Male Medical Record Linkage Risk",

author = "Erkens, {J. A.} and Klungel, {O. H.} and Herings, {R. M.} and Stolk, {R. P.} and Spoelstra, {J. A.} and Grobbee, {D. E.} and Leufkens, {H. G.}",

note = "Erkens, J A Klungel, O H Herings, R M C Stolk, R P Spoelstra, J A Grobbee, D E Leufkens, H G M eng Comment Research Support, Non-U.S. Gov't England Eur Heart J. 2002 Oct;23(20):1575-9. doi: 10.1053/euhj.2002.3173.",

year = "2002",

doi = "10.1053/euhj.2002.3173",

language = "English",

volume = "23",

pages = "1575--1579",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "20",

}

TY - JOUR

T1 - Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients

AU - Erkens, J. A.

AU - Klungel, O. H.

AU - Herings, R. M.

AU - Stolk, R. P.

AU - Spoelstra, J. A.

AU - Grobbee, D. E.

AU - Leufkens, H. G.

N1 - Erkens, J A Klungel, O H Herings, R M C Stolk, R P Spoelstra, J A Grobbee, D E Leufkens, H G M eng Comment Research Support, Non-U.S. Gov't England Eur Heart J. 2002 Oct;23(20):1575-9. doi: 10.1053/euhj.2002.3173.

PY - 2002

Y1 - 2002

N2 - AIMS: The aim of the present study was to investigate whether use of specific antibiotic drugs decreases the risk of coronary heart disease in diabetes mellitus type 2 patients. METHODS AND RESULTS: Data were obtained from the PHARMO Record Linkage System comprising pharmacy records and hospitalizations for all 450,000 residents of eight Dutch cities. In a nested case-control study among diabetes mellitus type 2 patients, 244 cases with a first hospitalization for coronary heart disease and 686 controls without coronary heart disease matched on age, sex, calendar time, and registration date in PHARMO RLS were selected. Use of antibiotic drugs among cases and controls was determined over 3 years prior to the event. Use of fluorquinolones for more than 14 days compared to no use of fluorquinolones was associated with a lower risk of coronary heart diseases (OR(adj)=0.30 (95%CI: 0.12-0.75)). No association between tetracycline, macrolide and lincosamide treatment, or other antibiotic drugs (penicillins, cephalosporines, sulphonamides and trimethoprim), and the risk of coronary heart disease was found. CONCLUSION: Our results suggest that treatment with fluorquinolones in doses commonly prescribed in routine clinical practice is associated with a reduction in the risk of coronary heart diseases among diabetes mellitus type 2 patients.

AB - AIMS: The aim of the present study was to investigate whether use of specific antibiotic drugs decreases the risk of coronary heart disease in diabetes mellitus type 2 patients. METHODS AND RESULTS: Data were obtained from the PHARMO Record Linkage System comprising pharmacy records and hospitalizations for all 450,000 residents of eight Dutch cities. In a nested case-control study among diabetes mellitus type 2 patients, 244 cases with a first hospitalization for coronary heart disease and 686 controls without coronary heart disease matched on age, sex, calendar time, and registration date in PHARMO RLS were selected. Use of antibiotic drugs among cases and controls was determined over 3 years prior to the event. Use of fluorquinolones for more than 14 days compared to no use of fluorquinolones was associated with a lower risk of coronary heart diseases (OR(adj)=0.30 (95%CI: 0.12-0.75)). No association between tetracycline, macrolide and lincosamide treatment, or other antibiotic drugs (penicillins, cephalosporines, sulphonamides and trimethoprim), and the risk of coronary heart disease was found. CONCLUSION: Our results suggest that treatment with fluorquinolones in doses commonly prescribed in routine clinical practice is associated with a reduction in the risk of coronary heart diseases among diabetes mellitus type 2 patients.

KW - Aged Case-Control Studies Control Groups Coronary Disease/prevention & control Diabetes Mellitus, Type 2/drug therapy Diabetic Angiopathies/prevention & control Female Fluoroquinolones/therapeutic use Humans Male Medical Record Linkage Risk

U2 - 10.1053/euhj.2002.3173

DO - 10.1053/euhj.2002.3173

M3 - Article

SN - 0195-668X

VL - 23

SP - 1575

EP - 1579

JO - European Heart Journal

JF - European Heart Journal

IS - 20

ER -